Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;239(7):2063-2081.
doi: 10.1007/s00213-022-06125-5. Epub 2022 Apr 7.

Treatment of opioid overdose: current approaches and recent advances

Stevie C Britch  1   2 , Sharon L Walsh  3   4   5   6   7
Affiliations
Review

Treatment of opioid overdose: current approaches and recent advances

Stevie C Britch et al. Psychopharmacology (Berl). 2022 Jul.

Abstract

Background: The USA has recently entered the third decade of the opioid epidemic. Opioid overdose deaths reached a new record of over 74,000 in a 12-month period ending April 2021. Naloxone is the primary opioid overdose reversal agent, but concern has been raised that naloxone is not efficacious against the pervasive illicit high potency opioids (i.e., fentanyl and fentanyl analogs).

Methods: This narrative review provides a brief overview of naloxone, including its history and pharmacology, and the evidence regarding naloxone efficacy against fentanyl and fentanyl analogs. We also highlight current advances in overdose treatments and technologies that have been tested in humans.

Results and conclusions: The argument that naloxone is not efficacious against fentanyl and fentanyl analogs rests on case studies, retrospective analyses of community outbreaks, pharmacokinetics, and pharmacodynamics. No well-controlled studies have been conducted to test this argument, and the current literature provides limited evidence to suggest that naloxone is ineffective against fentanyl or fentanyl analog overdose. Rather a central concern for treating fentanyl/fentanyl analog overdose is the rapidity of overdose onset and the narrow window for treatment. It is also difficult to determine if other non-opioid substances are contributing to a drug overdose, for which naloxone is not an effective treatment. Alternative pharmacological approaches that are currently being studied in humans include other opioid receptor antagonists (e.g., nalmefene), respiratory stimulants, and buprenorphine. None of these approaches target polysubstance overdose and only one novel approach (a wearable naloxone delivery device) would address the narrow treatment window.

Keywords: Fentanyl overdose; Nalmefene; Naloxone; Opioid overdose; Overdose reversal.

PubMed Disclaimer

Conflict of interest statement

Sharon Walsh serves on a Scientific Advisory Board for Opiant Pharmaceuticals and as an advisor for Pocket Naloxone.

References

    1. Abram AK (2017) Determination that REVEX (nalmefene hydrochloride injection), 0.1 milligram base/milliliter and 1.0 milligram base/milliliter, was not withdrawn from sale for reasons of safety or effectiveness. U.S. Food and Drug Administration. https://www.federalregister.gov/d/2017-23952
    1. Adapt Pharma Operations Limited (2016) FDA advisory committee on the most appropriate dose or doses of naloxone to reverse the effects of fife-threatening opioid overdose in the community settings. https://www.fda.gov/media/100409/download
    1. Adapt Pharma Operations Limited (2019) Narcan nasal spray package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208411s001lbl.pdf
    1. Ahmad FB, Rossen LM, Sutton P (2021) Provisional drug overdose death counts. Center for Disease Control and Prevention, National Center for Health Statistics. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
    1. Ahonen J, Olkkola KT, Hynynen M, Seppälä T, Ikävalko H, Remmerie B, Salmenperä M. Comparison of alfentanil fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery. Br J Anaesth. 2000;85:533–540. doi: 10.1093/bja/85.4.533. - DOI - PubMed